Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Ribosomal Protein L22 Double Nickase Plasmid (h): sc-417644-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Ribosomal Protein L22 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- Ribosomal Protein L22 Double Nickase Plasmid (h) and Ribosomal Protein L22 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting RPL22. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Ribosomal Protein L22 Antibody (D-7): sc-373993
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Ribosomal Protein L22 Double Nickase Plasmid (h) | sc-417644-NIC | 20 µg | $410.00 |
RPL22 encodes the human ribosomal protein L22, a structural component of the 60S large ribosomal subunit that helps coordinate rRNA architecture and supports efficient translation. Beyond its core role in ribosome biogenesis and protein synthesis, RPL22 has been linked to regulation of mRNA processing and cellular stress responses that intersect with proliferation and differentiation programs. Altered ribosomal protein dosage or function can disrupt translational control and nucleolar homeostasis, processes frequently studied in the context of cancer biology and ribosomopathies. RPL22 is therefore commonly investigated for its contribution to proteostasis, cell-cycle regulation, and context-dependent vulnerabilities arising from perturbed ribosome function.
Ribosomal Protein L22 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the RPL22 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within RPL22. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt RPL22 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of RPL22-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.